Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rostafuroxin genotype-response study in untreated hypertensive adults with type 2 diabetes
2011-000785-35Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rostafuroxin in essential hypertension and type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Office systolic blood pressure and Albuminuria. Started Mar 2012; status: terminated.
02
Drugs
rostafuroxin
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-000785-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000785-35.